Amgen Inc. $AMGN Shares Bought by Sapient Capital LLC

Sapient Capital LLC grew its position in shares of Amgen Inc. (NASDAQ:AMGN) by 60.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,619 shares of the medical research company’s stock after purchasing an additional 1,746 shares during the period. Sapient Capital LLC’s holdings in Amgen were worth $1,518,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. West Family Investments Inc. grew its stake in shares of Amgen by 1.1% during the third quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company’s stock valued at $779,000 after acquiring an additional 30 shares in the last quarter. Viawealth LLC lifted its stake in shares of Amgen by 0.4% in the third quarter. Viawealth LLC now owns 7,168 shares of the medical research company’s stock worth $2,023,000 after acquiring an additional 30 shares in the last quarter. LOM Asset Management Ltd lifted its stake in shares of Amgen by 1.2% in the third quarter. LOM Asset Management Ltd now owns 2,554 shares of the medical research company’s stock worth $721,000 after acquiring an additional 30 shares in the last quarter. Smith Salley Wealth Management boosted its holdings in Amgen by 0.3% in the fourth quarter. Smith Salley Wealth Management now owns 10,786 shares of the medical research company’s stock valued at $3,530,000 after purchasing an additional 30 shares during the last quarter. Finally, Evergreen Private Wealth LLC boosted its holdings in Amgen by 4.0% in the fourth quarter. Evergreen Private Wealth LLC now owns 785 shares of the medical research company’s stock valued at $257,000 after purchasing an additional 30 shares during the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on AMGN shares. Leerink Partners restated a “market perform” rating and set a $355.00 price objective on shares of Amgen in a report on Thursday, March 5th. Daiwa Securities Group decreased their price target on shares of Amgen from $410.00 to $390.00 and set an “outperform” rating for the company in a research report on Wednesday, May 13th. Piper Sandler dropped their price target on shares of Amgen from $432.00 to $427.00 and set an “overweight” rating for the company in a research note on Thursday. Wells Fargo & Company upped their price target on shares of Amgen from $375.00 to $390.00 and gave the company an “equal weight” rating in a report on Thursday, March 19th. Finally, The Goldman Sachs Group increased their price objective on shares of Amgen from $415.00 to $425.00 and gave the company a “buy” rating in a research note on Friday, May 1st. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $356.15.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the firm’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the transaction, the senior vice president directly owned 7,009 shares in the company, valued at approximately $2,269,023.57. This trade represents a 15.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 0.85% of the company’s stock.

Amgen Trading Down 0.6%

NASDAQ:AMGN opened at $324.39 on Tuesday. The company has a market cap of $175.07 billion, a PE ratio of 22.57, a P/E/G ratio of 3.28 and a beta of 0.44. The business’s 50 day moving average is $348.31 and its two-hundred day moving average is $343.59. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. Amgen Inc. has a 52 week low of $267.83 and a 52 week high of $391.29.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The business had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. During the same period in the previous year, the business earned $4.90 EPS. The business’s quarterly revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, analysts predict that Amgen Inc. will post 22.37 EPS for the current year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be issued a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 3.1%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s dividend payout ratio is 70.15%.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.